An international team of researchers working in the Boston and Singapore labs of Harvard Stem Cell Institute (HSCI) Blood Program leader Daniel Tenen, MD, recently identified new candidates for the treatment of an acute myeloid leukemia (AML) subtype caused by mutations of CEBPA, a tumor suppressor. The findings were published in two separate studies:
Harvard stem cell scientists have discovered that the clump of cells that gives rise to the embryonic heart also contains cells that form the heart’s plumbing, such as the aorta and the other great vessels.
Harvard Stem Cell Scientists have discovered that the same chemicals that stimulate muscle development in zebrafish can also be used to differentiate human stem cells into muscle cells in the laboratory, an historically challenging task that, now overcome, makes muscle cell therapy a more realistic clinical possibility. Read more about Human muscle stem cell therapy gets help from zebrafish